CombiMatrix Likely to Spin Out From Acacia In Q1 2007 as Firm Banks on CMDX Pipeline | GenomeWeb
CombiMatrix will likely spin off from parent company Acacia Research by the first quarter of 2007, roughly six months after it had originally anticipated doing so.
 
At the same time, the firm’s CombiMatrix Molecular Diagnostics subsidiary is readying a suite of diagnostic tests that it believes will put it ahead of rivals in the array-based molecular diagnostic space next year.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.